TNFSF13B and myasthenia gravis: Previous phase II clinical trials showed that belimumab, a BAFF‐specific monoclonal antibody, did not significantly improve clinical scores in MG patients.[38] In contrast, telitacicept, a dual‐target biologic inhibiting both BAFF and APRIL, demonstrated significant improvements in clinical scores and quality of life in MG patients in a recent phase II clinical trial conducted in China.[29] Although both drugs target the key molecule BAFF involved in B cell survival, the results of these two studies differ to some extent.